Unveiling the Pharmacological Mechanisms of Osteoking's anti-diabetic bone metabolism abnormality Through Fecal Microbiome and liver Metabolomics

Background: Osteoking (OK) is a famous Chinese patent medicine in Yunnan.It has the effect of treating fractures, femoral head necrosis, osteoarthropathy, and lumbar disc herniation.In recent years, it has been gradually found to have the effect of treating osteoporosis. Diabetic osteoporosis is a serious complication in skeletal systems caused by diabetes, and the mechanism is different from primary osteoporosis, which is related to metabolic disorders caused by diabetes. In this study, we briefly verify the effects of ok on the pharmacodynamics of db/db mice, focusing on the effects of fecal microbiome and liver metabolomics on diabetic osteoporosis, and then exploit the role of fecal microbiome and liver metabolomics in diabetic osteoporosis.Methods: Eight weeks old db/db male mice were randomly divided into model groups and administration groups (n=6), and WT mice were used as the blank control group (n=6). The administration group was given 0.1 ml / 10 g of OK for 10 weeks. The blood sugar of three groups of mice was measured and analyzed. The severity of the disease and the therapeutic effect of OK were evaluated by tissue pathological testing. Applicating the fecal 16S rRNA gene sequencing and liver metabolomics to analyze the effects of diabetic bone metabolism on intestinal flora and host metabolism and the therapeutic mechanism of OK.